Sangamo BioSciences, Inc.

Engineered DNA-binding proteins for the regulation of gene expression and for gene modification

Sangamo located Richmond, California was founded in 1995 and went public in 2000 on the NASDAQ Global Market (SGMO). The company is involved in the design and development of engineered zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification. The aim is to develop human therapeutics and applications in laboratory research reagents and plant agriculture.

Edward Lanphier (President, CEO)
H. Ward Wolff (Executive VP, CFO)
David G. Ichikawa (Senior VP, Business Development)
Dale Ando (VP, Therapeutic Development, CMO)
Ely Benaim (VP, Clinical Affairs)
Philip D. Gregory (VP, Research)
Ed Rebar (VP, Technology)
Greg Zante (VP, Finance & Administration)

Edward Lanphier
William G. Gerber
John W. Larson
Margaret A. Liu
Steven Mento
Thomas G. Wiggans
Michael C. Wood

Judith Campisi
Barrie Carter
Michael Gilman
Sir Aaron Klug
Gabor M. Rubanyi
Kevin Struhl

Point Richmond Tech Center II
501 Canal Blvd, Suite A100
Richmond, CA 94804
USA
Phone: +49-510-970-6000
Fax: +49-510-236-8951

ZFP TFs are novel transcription factors designed to regulate the expression of target endogenous genes.